ArticleGut pathogens2020
Colistin-resistant
Article in Gut pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Weissella as an emerging probiotic candidate for IBD: current evidence, challenges, and future perspectives".Antonie van Leeuwenhoek · 2026Review
- Genetic diversity and occurrence of antibiotic resistance genes from community wastewater in Dhaka and Cox's Bazar, Bangladesh.One health (Amsterdam, Netherlands) · 2026Article
- Silent Threat Evolution: Critically Important Carbapenem and Colistin Resistance Genes in the Natural Aquatic Environment.Antibiotics (Basel, Switzerland) · 2026Review
- Co-Occurrence and Molecular Characterization of ESBL-Producing and Colistin-ResistantFoods (Basel, Switzerland) · 2025Article
- Molecular characteristics of antimicrobial resistance and biofilm formation of bloodstream infection pathogens isolated from pediatric patients in Ukraine.IJID regions · 2025Article
- Prevalence, characteristics, and plasmid dynamics ofFrontiers in microbiology · 2025Article
- In-silico Analysis of a Novel MCR-1.1 Variant on an IncX4 Plasmid Attenuating Colistin Resistance in Multidrug-ResistantInfection and drug resistance · 2025Article
- Detection and Characterisation of Colistin-ResistantMicroorganisms · 2024Article
- Preclinical characterization and in silico safety assessment of three virulent bacteriophages targeting carbapenem-resistant uropathogenic Escherichia coli.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Whole genome analysis of multidrug-resistantMicrobiology spectrum · 2024Article
- Genomic Evaluation of Multidrug-Resistant Extended-Spectrum β-Lactamase (ESBL)-ProducingEnvironmental science & technology · 2024Article
- Genomic characterization of carbapenemase-producing Enterobacterales from Dhaka food markets unveils the spread of high-risk antimicrobial-resistant clones and plasmids co-carryingJAC-antimicrobial resistance · 2024Article
- First Report on the Occurrence and Antibiotic Resistance Profile of Colistin-ResistantMicroorganisms · 2024Article
- Mobile Colistin-Resistant GenesAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic-Resistant Bacteria Isolated from Street Foods: A Systematic Review.Antibiotics (Basel, Switzerland) · 2024Review
- First detection and characterization of mcr-1 colistin resistant E. coli from wild rat in Bangladesh.PloS one · 2024Article
- Carriage and within-host diversity ofEmerging microbes & infections · 2023Article
- Mobile Colistin Resistance (Antibiotics (Basel, Switzerland) · 2023Review
- Antimicrobial Resistance Profiles and Co-Existence of Multiple Antimicrobial Resistance Genes inAntibiotics (Basel, Switzerland) · 2023Article
- Worldwide Prevalence ofPathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundOne of the most significant public health concerns in today's world is the persistent upsurge of infections caused by multidrug resistant bacteria. As a result, clinicians are being forced to intervene with either less effective backup drugs or ones with substantial side-effects. Colistin is a last resort antimicrobial agent for the treatment of infections caused by multi-drug resistant gram-negative bacteria.
methods
resultsScreening of
conclusionWidespread dissemination of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.